The role of murine models of prostate cancer in drug target discovery and validation

Bibliography

• Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000;14(19):2410-34
   PubMed Web of Science ®Google Scholar
• Ahmad I, Sansom OJ, Leung HY. Advances in mouse models of prostate cancer. Expert Rev Mol Med 2008;10:e16
   PubMedGoogle Scholar
• Carver BS, Pandolfi PP. Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 2006;12(18):5305-11
   PubMed Web of Science ®Google Scholar
• Roy-Burman P, Wu H, Powell WC, et al. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 2004;11(2):225-54
   PubMed Web of Science ®Google Scholar
• Dunning WF. Prostate cancer in the rat. Natl Cancer Inst Monogr 1963;12:351-69
   PubMedGoogle Scholar
• Isaacs JT, Weissman RM, Coffey DS, Scott WW. Concepts in prostatic cancer biology: Dunning R-3327 H, HI, and AT tumors. Prog Clin Biol Res 1980;37:311-23
   PubMedGoogle Scholar
• Pollard M, Suckow MA. Hormone-refractory prostate cancer in the Lobund-Wistar rat. Exp Biol Med (Maywood) 2005;230(8):520-6
   PubMed Web of Science ®Google Scholar
• Aquilina JW, McKinney L, Pacelli A, et al. High grade prostatic intraepithelial neoplasia in military working dogs with and without prostate cancer. Prostate 1998;36(3):189-93
   PubMed Web of Science ®Google Scholar
• Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev 1998;17(4):361-71
   PubMed Web of Science ®Google Scholar
• Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9(11):4227-39
   PubMed Web of Science ®Google Scholar
• Shappell SB, Thomas GV, Roberts RL, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64(6):2270-305
   PubMed Web of Science ®Google Scholar
• Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002;62(11):2999-3004
   PubMed Web of Science ®Google Scholar
• Gingrich JR, Barrios RJ, Kattan MW, et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57(21):4687-91
   PubMed Web of Science ®Google Scholar
• Greenberg NM, Demayo FJ, Sheppard PC, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8(2):230-9
   PubMed Web of Science ®Google Scholar
• Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci USA 1998;95(26):15382-7
   PubMed Web of Science ®Google Scholar
• Abate-Shen C, Shen MM. Mouse models of prostate carcinogenesis. Trends Genet 2002;18(5):S1-5
   PubMed Web of Science ®Google Scholar
• Powell WC, Cardiff RD, Cohen MB, et al. Mouse strains for prostate tumorigenesis based on genes altered in human prostate cancer. Curr Drug Targets 2003;4(3):263-79
   PubMed Web of Science ®Google Scholar
• Sauer B, Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci USA 1988;85(14):5166-70
   PubMed Web of Science ®Google Scholar
• Dahia PL. PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 2000;7(2):115-29
   PubMed Web of Science ®Google Scholar
• Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58(2):204-9
   PubMed Web of Science ®Google Scholar
• Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19(4):348-55
   PubMed Web of Science ®Google Scholar
• Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4(3):209-21
   PubMed Web of Science ®Google Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2(8):584-93
   PubMed Web of Science ®Google Scholar
• Wang J, Eltoum IE, Lamartiniere CA. Genistein chemoprevention of prostate cancer in TRAMP mice. J Carcinog 2007;6:3
   PubMedGoogle Scholar
• Chanvitayapongs S, Draczynska-Lusiak B, Sun AY. Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport 1997;8(6):1499-502
   PubMed Web of Science ®Google Scholar
• Harper CE, Patel BB, Wang J, et al. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 2007;28(9):1946-53
   PubMed Web of Science ®Google Scholar
• Raina K, Singh RP, Agarwal R, Agarwal C. Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice. Cancer Res 2007;67(12):5976-82
   PubMed Web of Science ®Google Scholar
• Gupta S, Hastak K, Ahmad N, et al. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001;98(18):10350-5
   PubMed Web of Science ®Google Scholar
• Gupta S, Ahmad N, Marengo SR, et al. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res 2000;60(18):5125-33
   PubMed Web of Science ®Google Scholar
• Adhami VM, Siddiqui IA, Sarfaraz S, et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP Model depends on the stage of the disease. Clin Cancer Res 2009;15(6):1947-53
   PubMed Web of Science ®Google Scholar
• Huss WJ, Lai L, Barrios RJ, et al. Retinoic acid slows progression and promotes apoptosis of spontaneous prostate cancer. Prostate 2004;61(2):142-52
   PubMed Web of Science ®Google Scholar
• Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH. Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 2004;64(16):5891-6
   PubMed Web of Science ®Google Scholar
• Mori H, Fuchigami M, Inoue N, et al. Principle of the bark of Phellodendron amurense to suppress the cellular immune response: effect of phellodendrine on cellular and humoral immune responses. Planta Med 1995;61(1):45-9
   PubMed Web of Science ®Google Scholar
• Kumar AP, Bhaskaran S, Ganapathy M, et al. Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res 2007;13(9):2784-94
   PubMed Web of Science ®Google Scholar
• Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24(50):7465-74
   PubMed Web of Science ®Google Scholar
• Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10(6):594-601
   PubMed Web of Science ®Google Scholar
• Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008;118(9):3051-64
   PubMed Web of Science ®Google Scholar
• Wechter WJ, Leipold DD, Murray ED Jr, et al. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000;60(8):2203-8
   PubMed Web of Science ®Google Scholar
• Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004;64(9):3334-43
   PubMed Web of Science ®Google Scholar
• Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004;10(22):7727-37
   PubMed Web of Science ®Google Scholar
• Abdulkadir SA, Kim J. Genetically engineered murine models of prostate cancer: insights into mechanisms of tumorigenesis and potential utility. Future Oncol 2005;1(3):351-60
   PubMedGoogle Scholar
• Sargeant AM, Klein RD, Rengel RC, et al. Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer. Toxicol Pathol 2007;35(4):549-61
   PubMed Web of Science ®Google Scholar
• Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002;62(5):1370-6
   PubMed Web of Science ®Google Scholar
• Raghow S, Kuliyev E, Steakley M, et al. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. Cancer Res 2000;60(15):4093-7
   PubMed Web of Science ®Google Scholar
• Raina K, Blouin MJ, Singh RP, et al. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2007;67(22):11083-91
   PubMed Web of Science ®Google Scholar
• Raina K, Rajamanickam S, Singh RP, et al. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008;68(16):6822-30
   PubMed Web of Science ®Google Scholar
• Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 2008;14(23):7773-80
   PubMed Web of Science ®Google Scholar
• Schumann J, Prockl J, Kiemer AK, et al. Silibinin protects mice from T cell-dependent liver injury. J Hepatol 2003;39(3):333-40
   PubMed Web of Science ®Google Scholar
• Singh RP, Raina K, Deep G, et al. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 2009;15(2):613-21
   PubMed Web of Science ®Google Scholar
• Katona TM, Neubauer BL, Iversen PW, et al. Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res 2005;11(23):8358-63
   PubMed Web of Science ®Google Scholar
• Majumder PK, Yeh JJ, George DJ, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci USA 2003;100(13):7841-6
   PubMed Web of Science ®Google Scholar
• Ibaragi S, Yoshioka N, Li S, et al. Neamine inhibits prostate cancer growth by suppressing angiogenin-mediated rRNA transcription. Clin Cancer Res 2009;15(6):1981-8
   PubMed Web of Science ®Google Scholar
• Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997;94(15):8099-103
   PubMed Web of Science ®Google Scholar
• Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60(9):2444-8
   PubMed Web of Science ®Google Scholar
• Haga K, Tomioka A, Liao CP, et al. PTEN knockout prostate cancer as a model for experimental immunotherapy. J Urol 2009;181(1):354-62
   PubMed Web of Science ®Google Scholar
• Martiniello-Wilks R, Dane A, Mortensen E, et al. Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies. Anticancer Res 2003;23(3B):2633-42
   PubMed Web of Science ®Google Scholar
• Isayeva T, Chanda D, Kallman L, et al. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 2007;67(12):5789-97
   PubMed Web of Science ®Google Scholar
• Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2002;2(1):11-8
   PubMed Web of Science ®Google Scholar
• Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003;17(5):545-80
   PubMed Web of Science ®Google Scholar
• Hsieh CL, Xie Z, Liu ZY, et al. A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals. J Mol Endocrinol 2005;35(2):293-304
   PubMed Web of Science ®Google Scholar
• Lyons SK, Lim E, Clermont AO, et al. Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice. Cancer Res 2006;66(9):4701-7
   PubMed Web of Science ®Google Scholar
• Ellwood-Yen K, Wongvipat J, Sawyers C. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Res 2006;66(21):10513-6
   PubMed Web of Science ®Google Scholar
• Liao CP, Zhong C, Saribekyan G, et al. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 2007;67(15):7525-33
   PubMed Web of Science ®Google Scholar
• Cheng L, Fu J, Tsukamoto A, Hawley RG. Use of green fluorescent protein variants to monitor gene transfer and expression in mammalian cells. Nat Biotechnol 1996;14(5):606-9
   PubMed Web of Science ®Google Scholar
• Burton DW, Geller J, Yang M, et al. Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. Prostate 2005;62(3):275-81
   PubMed Web of Science ®Google Scholar
• Nastiuk KL, Liu H, Hamamura M, et al. In vivo MRI volumetric measurement of prostate regression and growth in mice. BMC Urol 2007;7:12
   Google Scholar
• Chen AP, Albers MJ, Cunningham CH, et al. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience. Magn Reson Med 2007;58(6):1099-106
   PubMed Web of Science ®Google Scholar
• Song SK, Qu Z, Garabedian EM, et al. Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model. Cancer Res 2002;62(5):1555-8
   PubMed Web of Science ®Google Scholar
• Ratnacaram CK, Teletin M, Jiang M, et al. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci USA 2008;105(7):2521-6
   PubMed Web of Science ®Google Scholar
• Acevedo VD, Gangula RD, Freeman KW, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007;12(6):559-71
   PubMed Web of Science ®Google Scholar
• Oyama N, Ponde DE, Dence C, et al. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2004;45(3):519-25
   PubMed Web of Science ®Google Scholar
• Yang YS, Zhang X, Xiong Z, Chen X. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol 2006;33(3):371-80
   PubMed Web of Science ®Google Scholar
• Garrison JC, Rold TL, Sieckman GL, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 2007;48(8):1327-37
   PubMed Web of Science ®Google Scholar
• Zhang L, Gao L, Zhao L, et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res 2007;67(12):5859-64
   PubMed Web of Science ®Google Scholar
• Zhao M, Geller J, Ma H, et al. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci USA 2007;104(24):10170-4
   PubMed Web of Science ®Google Scholar